Evidence map›Paper›PMID 28153760›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2017

Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Kyle J Isaacson, M Martin Jensen, Nithya B Subrahmanyam, Hamidreza Ghandehari

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Biorobotic Drug Delivery for Biomedical Applications.Molecules (Basel, Switzerland) · 2024
    Review
  14. Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Synthetic living materials in cancer biology.Nature reviews bioengineering · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kyle J IsaacsonDepartment of Bioengineering, University of Utah, Salt Lake City, UT, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, USA.
M Martin JensenDepartment of Bioengineering, University of Utah, Salt Lake City, UT, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, USA.
Nithya B SubrahmanyamDepartment of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, USA.
Hamidreza GhandehariDepartment of Bioengineering, University of Utah, Salt Lake City, UT, USA; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA; Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, USA. Electronic address: hamid.ghandehari@utah.edu.
University of Utah · US

Funding

Engineering Polymers For Gene Therapy of Head CancerR01CA107621 · NCI · UNIVERSITY OF UTAH · PI GHANDEHARI, HAMID · 2005 to 2014
$2.5M
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic CarcinomaR42CA168123 · NCI · THERATARGET · PI CHENEY, DARWIN LEROY, GHANDEHARI, HAMID · 2016 to 2019
$1.5M
NCI NIH HHS R01 CA107621NCI NIH HHS R42 CA168123
6 · The paper itself

Abstract

While commonly known for degradation of the extracellular matrix, matrix metalloproteinases (MMPs) exhibit broad potential for use in targeting of bioactive and imaging agents in cancer treatment. MMPs are upregulated at all stages of expression in cancers. A comprehensive analysis of published literature on expression of all MMP subtypes at the genetic, protein, and activity levels in normal and diseased tissues indicate targeting applicability in a variety of cancers. This expression significantly increases at advanced cancer stages, providing an improved opportunity for controlled release in higher-stage patients. Since MMPs are integral at every stage of metastasis, MMP roles in cancer are discussed with a focus on MMP distribution and mobility within cells and tumors for cancer targeting applications. Several strategies for MMP utilization in targeting - such as matrix degradation, MMP cleavage, MMP binding, and MMP-induced environmental changes - are addressed.

Indexed as

Molecular Targeted TherapyAnimalsHumansMatrix MetalloproteinasesNeoplasmsUp-RegulationMatrix MetalloproteinasesCancerControlled releaseDrug targetingExpressionMatrix metalloproteinasesUpregulation

Identifiers

PMID28153760
PMCPMC5537048
OpenAlexW2585413268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.